Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off

Monash University Engages LaNeo MDMA

Australian Monash University’s psychedelics research lab has contracted MDXX-class molecules developer PharmAla Biotech to manufacture and supply its clinical-grade MDMA LaNeo for an upcoming Phase 2 clinical study.

Delivery is set for this summer.

This is PharmAla’s fourth MDMA supply for a major clinical trial in Australia. Notably, PharmAla is the first publicly-traded company to manufacture GMP MDMA and the first to make two GMP-compliant psychedelic APIs available to researchers.

See Also: EXCLUSIVE - MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opp

CEO Nick Kadysh says that Australia is “rapidly becoming one of the most exciting locations for MDMA research anywhere in the world. The latest supply deal helps PharmAla continue “to establish itself as the premier supplier of choice for clinical MDMA researchers in Australia and globally," he added.

The Monash lab is led by acclaimed Prof. Paul Liknaitzky. He is also the co-founder and CSO of several psychedelic clinics, the first of which is set to open in Melbourne this year. 

Clearmind's Upcoming Trial Of CMND-100

Israeli next-gen psychedelics company Clearmind Medicine Inc. CMND announced additional preparations toward the expected start of its first Phase 1 clinical trial, including the engagement of an experienced Contract Research Organization (CRO) to support the company in the development of its MEAI-based compound CMND-100 for the treatment of Alcohol Use Disorder (AUD.)

See Also: EXCLUSIVE - Next-Generation Psychedelics, MEAI - The Road Ahead

Specifically, the CRO will act as a project manager, support in regulatory affairs, site selection and initiation, recruitment support, clinical monitoring, data management, among other tasks.

The company focuses on the discovery and development of novel psychedelic-derived therapeutics to tackle widespread and underserved health problems, with the primary goal of commercializing them as regulated medicines, foods or supplements.

Clearmind’s IP currently consists of 14 patent families. CEO Adi Zuloff-Shani says the company is “entering an advanced stage” according to timelines, and is closer “to being able to treat alcoholism, a common problem that affects both young people and adults.”

Benzinga’s PCC 2023

Missed our Psychedelics Capital Conference? Here's some EXCLUSIVE coverage from the event’s second edition:

• Investing In The Unique Growth Market Of Psychedelics

• Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'

• Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga's Psychedelics Capital Conference

• In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

• Making The World A Better Place, How Psychedelics Are Helping

Photo: Benzinga edit with photo by Pexels.